MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody

Autor: Pei-Jung Lee, Chien-Min Hung, Ai-Jen Yang, Cheng-Yu Hou, Hung-Wen Chou, Yi-Chung Chang, Wen-Cheng Chu, Wen-Yen Huang, Wen-Chih Kuo, Chia-Chun Yang, Kuo-I Lin, Kuo-Hsuan Hung, Li-Chun Chang, Kang-Yun Lee, Han-Pin Kuo, Kung-Ming Lu, Hsin-Chih Lai, Ming-Liang Kuo, Wan-Jiun Chen
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Gut Microbes, Vol 16, Iss 1 (2024)
Druh dokumentu: article
ISSN: 19490976
1949-0984
1949-0976
DOI: 10.1080/19490976.2024.2380061
Popis: Cancer immunotherapy has been regarded as a promising strategy for cancer therapy by blocking immune checkpoints and evoking immunity to fight cancer, but its efficacy seems to be heterogeneous among patients. Manipulating the gut microbiota is a potential strategy for enhancing the efficacy of immunotherapy. Here, we report that MS-20, also known as “Symbiota®”, a postbiotic that comprises abundant microbial metabolites generated from a soybean-based medium fermented with multiple strains of probiotics and yeast, inhibited colon and lung cancer growth in combination with an anti-programmed cell death 1 (PD1) antibody in xenograft mouse models. Mechanistically, MS-20 remodeled the immunological tumor microenvironment by increasing effector CD8+ T cells and downregulating PD1 expression, which were mediated by the gut microbiota. Fecal microbiota transplantation (FMT) from mice receiving MS-20 treatment to recipient mice increased CD8+ T-cell infiltration into the tumor microenvironment and significantly improved antitumor activity when combined with anti-PD1 therapy. Notably, the abundance of Ruminococcus bromii, which increased following MS-20 treatment, was positively associated with a reduced tumor burden and CD8+ T-cell infiltration in vivo. Furthermore, an ex vivo study revealed that MS-20 could alter the composition of the microbiota in cancer patients, resulting in distinct metabolic pathways associated with favorable responses to immunotherapy. Overall, MS-20 could act as a promising adjuvant agent for enhancing the efficacy of immune checkpoint-mediated antitumor therapy.
Databáze: Directory of Open Access Journals
Externí odkaz: